Results 41 to 50 of about 28,228 (226)

Is losartan the drug for all seasons?

open access: yesCurrent Opinion in Pharmacology, 2012
Francesco Ramirez is the Dr. Amy and James Elster Professor of Molecular Biology (Connective Tissue Diseases) in the Department of Pharmacology and Systems Therapeutics at the Mount Sinai School of Medicine in New York City. His long-standing research interest focuses on the role of ECM proteins in health and disease.
Francesco Ramirez, Daniel B. Rifkin
openaire   +3 more sources

Improvement of Losartan Transdermal Permeation using Oleic Acid Pretreatment: in Vitro Observation and in Vivo Prediction

open access: yesPharmaceutical Sciences and Research, 2019
The effect of oleic acid on losartan transdermal permeation has been observed to explore its ability as chemical enhancer. Potassium losartan solutions in citric buffer pH 5.0 were made in two levels of concentration i.e.
Annas Binarjo, Akhmad Kharis Nugroho
doaj  

Pharmacokinetic interaction of drugs, the metabolisable cytochrome P450 isoenzyme CYP2C9

open access: yesФармакокинетика и Фармакодинамика, 2020
The role of cytochrome P450 isoforms CYP2C9 and in the metabolism of losartan described. Losartan pharmacokinetics data in humans and laboratory animals are presented.
O. G. Gribakina   +4 more
doaj  

Protective Role of Angiotensin II Type 1 Receptor Blocker on Short Time Effect of Oleic Acid Induced Lung and Kidney Injury

open access: yesInternational Journal of Preventive Medicine, 2021
Backgrounds: Acute respiratory distress syndrome (ARDS) causes high mortality rate in clinic, and the pathogenesis of this syndrome may interact with renin angiotensin system (RAS) components.
Ardeshir Talebi   +8 more
doaj   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post   +4 more
wiley   +1 more source

Chronic Losartan Treatment Up-Regulates AT1R and Increases the Heart Vulnerability to Acute Onset of Ischemia and Reperfusion Injury in Male Rats.

open access: yesPLoS ONE, 2015
Inhibition of angiotensin II type 1 receptor (AT1R) is an important therapy in the management of hypertension, particularly in the immediate post-myocardial infarction period.
Minwoo A Song   +2 more
doaj   +1 more source

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib

open access: yesMolecules, 2022
Axitinib is one of the most potent inhibitors of the vascular endothelial growth factor (VEGF) receptor and shows strong antitumor activity toward various malignant tumors.
Ying Fu   +8 more
doaj   +1 more source

Network medicine and systems pharmacology approaches to predicting adverse drug effects

open access: yesBritish Journal of Pharmacology, EarlyView.
Identifying and understanding the relationships between drug intake and adverse effects that can occur due to inadvertent molecular interactions between drugs and targets is a difficult task, especially considering the numerous variables that can influence the onset of such events.
Alessio Funari   +2 more
wiley   +1 more source

Case Series of Patients With FGFR1‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway).
Sakshi Jhawar   +5 more
wiley   +1 more source

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

open access: yesPLoS ONE, 2019
There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth factor-β (
Zoe White   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy